Higher priced drugs are not cost effective for diabetic macular edema, US study finds

In comparsion with treatment with the low cost antivascular endothelial growth factor (VEGF) drug bevacizumab (Avastin), the more expensive alternatives aflibercept (Eylea) and ranibizumab (Lucentis) are not cost effective for diabetic macular edema, a new study has found.1